Siemens Healthineers AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SMMNY research report →
Price Chart
About the company
Siemens Healthineers AG (SMMNY), operating through its various subsidiaries, is a global enterprise that provides a comprehensive suite of diagnostic and therapeutic medical products and services. These offerings are extended to healthcare professionals and institutions across numerous international markets, including Germany, the United States, the broader European continent, the CIS region, Africa, the Middle East, the Americas, the Asia Pacific region, Japan, and China. The company's business is structured across four primary divisions: Imaging, Diagnostics, Varian, and Advanced Therapies.
- CEO
- Bernhard Montag
- IPO
- 2018
- Employees
- 74,000
- HQ
- Forchheim, BV, DE
Get TickerSpark's AI analysis on SMMNY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $26.77B
- P/E
- 21.80
- Fwd P/E
- 19.97
- PEG
- 5.95
- P/S
- 2.04
- P/B
- 2.42
- EV/EBITDA
- 10.11
- Div Yield
- 2.32%
- Gross Margin
- 38.57%
- Op Margin
- 14.17%
- Net Margin
- 9.37%
- ROE
- 11.72%
- ROIC
- 7.76%
Latest fiscal year · YoY change
- Revenue
- $23.63B+7.2%
- Gross Profit
- $9.11B+7.1%
- Op Income
- $3.19B
- Net Income
- $2.21B+9.5%
- EPS
- $1.00+10.6%
- OCF Growth
- +13.1%
- FCF Growth
- +14.5%
- 52W High
- $27.46
- 52W Low
- $19.20
- 50D MA
- $22.61
- 200D MA
- $21.89
- Beta
- 0.83
- RSI (14)
- 60
- Avg Volume
- 60.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Siemens Healthineers ended fiscal 2026 with strong core growth and book-to-bill, while setting a more cautious fiscal 2027 guide that reflects China, inflation, and portfolio changes.· November 5, 2026
- Synergetic core revenue grew 8.1% in Q4 and 6.1% for fiscal 2026, with group comparable growth at 4% for the year.
- Q4 equipment book-to-bill was 1.15, supported by value partnerships and strong demand across geographies.
- Adjusted EPS was EUR 2.42 for fiscal 2026; management said EUR 2.30 was the clean base after tariff refunds and one-offs.
- Diagnostics revenue stabilized sequentially but still fell 4.2% year over year in Q4; Quest Diagnostics extended its relationship for 5 years.
- FY27 guidance calls for 4% to 5% comparable revenue growth and adjusted EPS of EUR 2.20 to EUR 2.40, with extra adjustments tied to spin-off, Diagnostics carve-out, and ultrasound changes.
In Q4, synergetic core revenue grew 8.1%, group revenue grew 5.9%, and the equipment book-to-bill ratio was 1.15. For fiscal 2026, the synergetic core grew 6.1%, group comparable growth was 4%, and adjusted EPS was EUR 2.42; management said EUR 2.30 was the adjusted EPS excluding tariff refunds and certain one-offs, versus an initial guidance range of EUR 2.20 to EUR 2.40. Diagnostics revenue declined 4.2% year over year in Q4, while its margin improved sequentially to a normalized level of around 4% after tariff refunds and one-offs. Looking ahead to fiscal 2027, the company expects comparable revenue growth of 4% to 5% and adjusted EPS of EUR 2.20 to EUR 2.40. Management also guided to financial income net of minus EUR 440 million to minus EUR 400 million, additional adjustments of EUR 600 million related to discrete decisions, and a tax rate of 24% to 26%.
Bernhard Montag framed the quarter as a strong finish to fiscal 2026 and used the call to emphasize corporate clarity, portfolio focus, and the next phase of the company after the planned Siemens spin-off. He highlighted the planned transition to the Healthineers brand, the Diagnostics carve-out toward a stand-alone company by mid-calendar year 2028, and the focus on noncommunicable diseases through imaging, precision therapy, and healthcare AI. His tone was confident and strategic, stressing innovation leadership, customer partnerships, and the launch of Accela in radiation therapy as evidence of momentum.
Jochen Schmitz focused on the financial bridge from 2026 to 2027, stressing that the guide is deliberately prudent and incorporates known headwinds from China, inflation, portfolio changes, and refinancing. He said cash conversion has been between 0.8 and 0.9 over the last 3 years, with average free cash flow of around EUR 2.5 billion per year, and noted that net financial income should worsen to minus EUR 440 million to minus EUR 400 million in FY27 from minus EUR 300 million in FY26. He also said Siemens Healthineers has refinanced 70% of loan volume, sees a pro forma average interest rate of around 2.5% per annum, and plans a stable dividend of EUR 1 per share, equal to a 50% payout ratio of net income.
Analysts pressed on whether the FY27 guide had enough buffer for worse inflation, how conservative China assumptions were, why imaging growth is not stronger despite a 1.15 book-to-bill, and whether U.S. election outcomes or Section 232 tariffs would change demand. Management said the guide already includes a prudent EUR 0.15 EBIT headwind for inflation, a slight revenue decline assumption in China for the synergetic core, and no material demand change expected from midterm elections; on Section 232, they said there was no news and they remain optimistic about a rational outcome. In Diagnostics, management said the mid-teens margin ambition remains intact, with about EUR 400 million of additional savings targeted, and on the ultrasound business they said the general imaging ultrasound system sales were intentionally slowed and the company is focusing on procedural ultrasound and associated services.
The call showed sustained demand in the synergetic core, with strong Q4 growth, a 1.15 book-to-bill, and healthy regional performance in the Americas and APJ. Management also pointed to several long-duration growth levers: Accela in radiation therapy, expanding value partnerships, and Diagnostics stabilization with a renewed Quest contract. The company said it is entering a clearer strategic phase after the spin-off and carve-out, while still targeting double-digit adjusted EPS growth over the medium term.
The main concerns were China weakness, inflation and FX pressure, and significant portfolio disruption from the ultrasound focus and Diagnostics carve-out. Diagnostics still posted a 4.2% year-over-year revenue decline in Q4, and management acknowledged that Chinese market rebasing caused a major profit pool decline in 2026. FY27 also includes EUR 600 million of additional adjustments and rising financial income headwinds, while management said some of the expected benefits from Accela and Transform4Future will take time to materialize.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 23.9%
- Shares Outstanding
- 1.12B
- Float Shares
- 266.60M
Congressional trading
Senate and House stock disclosures for SMMNY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Held by 3 ETFs
Biggest fund positions in SMMNY by dollar value.
Our SMMNY coverage
Recent articles, reports, and earnings notes.
No research on SMMNY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SMMNY report →Siemens Healthineers AG (SMMNY) Q4 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Siemens Healthineers AG (SMMNY) Discusses Foreign Exchange and Tariff Impacts on Q4 Revenue and Earnings Prepared Remarks Transcript
seekingalpha.com · Sep 30
Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers
businesswire.com · Sep 27
Siemens Healthineers (OTCMKTS:SMMNY) Stock Price Down 0.2% – Here’s What Happened
defenseworld.net · Sep 9
Siemens Healthineers: Successful Investment, Updating For H2 2026
seekingalpha.com · Aug 23
Siemens Healthineers AG (SMMNY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Jul 31
Siemens Healthineers Cuts Revenue Outlook on Diagnostics Weakness
wsj.com · Jul 31
Siemens Healthineers cuts revenue forecast citing diagnostics weakness
reuters.com · Jul 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.